Do analysts recommend GRDX or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRDX or ENVB more profitable?

Entero Therapeutics' return on equity of -49.81% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% Enveric Biosciences N/A -220.97% -177.47%

Do analysts prefer ENVB or LGVN?

Longeveron has a consensus price target of $5.50, indicating a potential upside of 641.14%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer ALLR or ENVB?

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 682.44%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Allarity Therapeutics is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALLR or ENVB more profitable?

Allarity Therapeutics' return on equity of -109.94% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% Enveric Biosciences N/A -220.97% -177.47%

Do analysts prefer ENVB or QNTM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ENVB or QNTM?

Quantum Biopharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enveric Biosciences N/A N/A -$8.77M -$23.54 N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is ENVB or QNTM more profitable?

Enveric Biosciences' return on equity of -220.97% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Enveric Biosciences N/A -220.97% -177.47% Quantum Biopharma N/A -941.54% -224.41%

Do analysts prefer DARE or ENVB?

Dare Bioscience presently has a consensus target price of $10.00, indicating a potential upside of 643.49%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Dare Bioscience is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DARE or ENVB more profitable?

Dare Bioscience's return on equity of 0.00% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Enveric Biosciences N/A -220.97% -177.47%

Enveric Biosciences (ENVB) Competitors

$1.69 +0.09 (+5.63%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$1.66 -0.03 (-1.78%)

As of 08/4/2026 07:56 PM Eastern

Compare

ENVB vs. GRDX, LGVN, ALLR, QNTM, and DARE

Should you buy Enveric Biosciences stock or one of its competitors? MarketBeat compares Enveric Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enveric Biosciences include Entero Therapeutics (GRDX), Longeveron (LGVN), Allarity Therapeutics (ALLR), Quantum Biopharma (QNTM), and Dare Bioscience (DARE).

How does Enveric Biosciences compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and Enveric Biosciences (NASDAQ:ENVB) are related small-cap companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Entero Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Enveric Biosciences' average media sentiment score of 0.80 beat Entero Therapeutics' score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Enveric Biosciences	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Entero Therapeutics' return on equity of -49.81% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Enveric Biosciences	N/A	-220.97%	-177.47%

Entero Therapeutics has higher revenue and earnings than Enveric Biosciences. Entero Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	475.06	-$6.39M	-$1.88	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

Summary

Entero Therapeutics beats Enveric Biosciences on 6 of the 11 factors compared between the two stocks.

How does Enveric Biosciences compare to Longeveron?

Enveric Biosciences (NASDAQ:ENVB) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Enveric Biosciences has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A
Longeveron	$1.20M	19.26	-$22.70M	-$1.13	N/A

Enveric Biosciences has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Longeveron's return on equity of -202.41% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-220.97%	-177.47%
Longeveron	-1,844.49%	-202.41%	-140.67%

Enveric Biosciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market.

Longeveron has a consensus price target of $5.50, indicating a potential upside of 641.14%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by insiders. Comparatively, 7.4% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Longeveron had 1 more articles in the media than Enveric Biosciences. MarketBeat recorded 1 mentions for Longeveron and 0 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 0.80 beat Longeveron's score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Enveric Biosciences	Positive
Longeveron	Neutral

Summary

Longeveron beats Enveric Biosciences on 9 of the 15 factors compared between the two stocks.

How does Enveric Biosciences compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Allarity Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

In the previous week, Enveric Biosciences' average media sentiment score of 0.80 beat Allarity Therapeutics' score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Allarity Therapeutics	Neutral
Enveric Biosciences	Positive

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 682.44%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Allarity Therapeutics is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Enveric Biosciences has lower revenue, but higher earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	65.13	-$11.23M	-$0.72	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

Allarity Therapeutics' return on equity of -109.94% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Enveric Biosciences	N/A	-220.97%	-177.47%

Summary

Allarity Therapeutics beats Enveric Biosciences on 7 of the 13 factors compared between the two stocks.

How does Enveric Biosciences compare to Quantum Biopharma?

Enveric Biosciences (NASDAQ:ENVB) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Quantum Biopharma had 6 more articles in the media than Enveric Biosciences. MarketBeat recorded 6 mentions for Quantum Biopharma and 0 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 0.80 beat Quantum Biopharma's score of 0.58 indicating that Enveric Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Enveric Biosciences	Positive
Quantum Biopharma	Positive

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Enveric Biosciences' return on equity of -220.97% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-220.97%	-177.47%
Quantum Biopharma	N/A	-941.54%	-224.41%

Enveric Biosciences has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Quantum Biopharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Summary

Enveric Biosciences beats Quantum Biopharma on 7 of the 10 factors compared between the two stocks.

How does Enveric Biosciences compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Enveric Biosciences has lower revenue, but higher earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	19.69	-$13.40M	-$0.95	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

Dare Bioscience's return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Enveric Biosciences	N/A	-220.97%	-177.47%

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dare Bioscience presently has a consensus target price of $10.00, indicating a potential upside of 643.49%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Dare Bioscience is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Enveric Biosciences' average media sentiment score of 0.80 beat Dare Bioscience's score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Dare Bioscience	Neutral
Enveric Biosciences	Positive

Dare Bioscience has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Summary

Dare Bioscience beats Enveric Biosciences on 8 of the 13 factors compared between the two stocks.

Get Enveric Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENVB vs. The Competition

Export

Metric	Enveric Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.89M	$11.49B	$6.83B	$12.76B
Dividend Yield	N/A	2.73%	2.59%	10.01%
P/E Ratio	-0.07	791.62	279.14	25.53
Price / Sales	N/A	736.23	595.23	94.29
Price / Cash	N/A	71.54	72.11	49.39
Price / Book	0.24	10.88	13.07	6.11
Net Income	-$8.77M	$2.81B	$3.48B	$347.58M
7 Day Performance	27.07%	2.73%	3.43%	4.91%
1 Month Performance	16.55%	-3.09%	-2.77%	-2.06%
1 Year Performance	-88.36%	191.02%	73.12%	21.03%

Enveric Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENVB Enveric Biosciences	0.7507 of 5 stars	$1.69 +5.6%	N/A	-87.8%	$5.89M	N/A	N/A	20
GRDX Entero Therapeutics	N/A	$2.73 -8.8%	N/A	N/A	$18.84M	$40K	N/A	9
LGVN Longeveron	1.7277 of 5 stars	$0.60 -0.5%	$5.50 +819.7%	-56.6%	$18.63M	$1.20M	N/A	20	Upcoming Earnings Gap Up
ALLR Allarity Therapeutics	1.7243 of 5 stars	$1.17 -0.8%	$10.25 +776.1%	+29.7%	$18.62M	$320K	N/A	10	Gap Up
QNTM Quantum Biopharma	0.6954 of 5 stars	$2.82 -6.0%	N/A	-89.7%	$18.04M	N/A	N/A	N/A	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENVB) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enveric Biosciences (ENVB) Competitors

ENVB vs. GRDX, LGVN, ALLR, QNTM, and DARE

How does Enveric Biosciences compare to Entero Therapeutics?

Summary

How does Enveric Biosciences compare to Longeveron?

Summary

How does Enveric Biosciences compare to Allarity Therapeutics?

Summary

How does Enveric Biosciences compare to Quantum Biopharma?

Summary

How does Enveric Biosciences compare to Dare Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enveric Biosciences (ENVB) Competitors

ENVB vs. GRDX, LGVN, ALLR, QNTM, and DARE

How does Enveric Biosciences compare to Entero Therapeutics?

Which has more risk & volatility, GRDX or ENVB?

Do insiders & institutionals believe in GRDX or ENVB?

Does the media favor GRDX or ENVB?

Do analysts recommend GRDX or ENVB?

Is GRDX or ENVB more profitable?

Which has better earnings and valuation, GRDX or ENVB?

Summary

How does Enveric Biosciences compare to Longeveron?

Which has stronger earnings & valuation, ENVB or LGVN?

Is ENVB or LGVN more profitable?

Which has more volatility & risk, ENVB or LGVN?

Do analysts prefer ENVB or LGVN?

Do institutionals and insiders have more ownership in ENVB or LGVN?

Does the media prefer ENVB or LGVN?

Summary

How does Enveric Biosciences compare to Allarity Therapeutics?

Do insiders and institutionals hold more shares of ALLR or ENVB?

Which has more risk and volatility, ALLR or ENVB?

Does the media refer more to ALLR or ENVB?

Do analysts prefer ALLR or ENVB?

Which has higher valuation & earnings, ALLR or ENVB?

Is ALLR or ENVB more profitable?

Summary

How does Enveric Biosciences compare to Quantum Biopharma?

Does the media prefer ENVB or QNTM?

Do institutionals & insiders hold more shares of ENVB or QNTM?

Is ENVB or QNTM more profitable?

Which has more volatility and risk, ENVB or QNTM?

Do analysts prefer ENVB or QNTM?

Which has better valuation and earnings, ENVB or QNTM?

Summary

How does Enveric Biosciences compare to Dare Bioscience?

Which has stronger valuation & earnings, DARE or ENVB?

Is DARE or ENVB more profitable?

Do insiders & institutionals believe in DARE or ENVB?

Do analysts prefer DARE or ENVB?

Does the media refer more to DARE or ENVB?

Which has more risk & volatility, DARE or ENVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools